Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Report any abdominal pain, changes in bowel habits, or digestive symptoms immediately, as early intervention can prevent complications
Through this management of GLP-1 use, Excellus BCBS has realized cost savings, as indicated by the graph below: Excellus BCBS is using what appears to be the most sensible weight loss GLP-1 prior authorization criteria in the marketplace, without significantly disrupting rebates. -USI Partner What we know about the future of GLP-1 drugs In 2024, there were significant advancements with GLP-1 indications
Bajt ML, Ho YS, Vonderfecht SL, Jaeschke H
Without sufficient interventions to manage this pandemic, the number of people with diabetes worldwide is expected to increase to 578 million people (10.2% of the population) by 2030 and 700 million (10.9%) by 2045 [1]
According to the STEP 1 trial, which studied semaglutide for weight loss: Participants lost an average of 15% of their body weight over 68 weeks (1 year, 4 months)
